In recent years, the therapeutic potential of estrogen receptor beta (ERβ) in breast cancer, prostate cancer, lung cancer, the nervous system, and bone tissue has been revealed, and this target has attracted more and more attention [1,2,3,4]. Here, ESR2 is linked to lung cancer.